Tisento Therapeutics
Sara Hagmeier currently serves as Sr Director Finance and Operations at Tisento Therapeutics, overseeing the company's Finance, Accounting, HR, and IT functions since July 2023. Prior to this role, Sara was Director of Finance, IT and HR Operations at Cyclerion from December 2022 to July 2023, where responsibilities included managing daily business operations and implementing processes in a dynamic environment. Sara also held the position of Director of Accounting Operations & Procure to Pay at Cyclerion Therapeutics between April 2019 and December 2022, focusing on contracts, procurement, accounts payable, payroll, and other financial operations. Earlier experience includes managing accounts payable operations at Ironwood Pharmaceuticals and overseeing corporate finance at BirdDog Solutions. Sara's educational background includes an MBA from the D'Amore-McKim School of Business at Northeastern University and a Bachelor’s degree in Business Administration from Strayer University.
This person is not in any teams
This person is not in any offices
Tisento Therapeutics
Ti sento means “I hear you" in Italian. At Tisento Therapeutics, we believe that meaningful innovation requires understanding the problem, and that starts with listening. First and foremost, we listen to those impacted by debilitating diseases to understand the daily challenges they face. We also listen to healthcare providers, patient advocates, regulatory agencies, and scientific data. All these inputs inform our thinking and shape how we conduct our research, design our trials, and evolve our company. We are on a mission to deliver medicines that address what matters most. Our lead candidate is zagociguat (formerly CY6463), a Phase 2, first-in-class, brain-penetrant sGC stimulator, which is advancing in MELAS and other genetic mitochondrial diseases. Zagociguat is ideally suited to treat mitochondrial diseases with both CNS and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness.